Literature DB >> 22302770

The effect on peritoneal dialysis pathogens of changing topical antibiotic prophylaxis.

Dwayne A Pierce1, John C Williamson, Vicki S Mauck, Gregory B Russell, Elizabeth Palavecino, John M Burkart.   

Abstract

BACKGROUND: Prophylactic gentamicin 0.1% cream has demonstrated efficacy in preventing both exit-site infection (ESI) and peritonitis attributable to gram-positive and gram-negative organisms; however, the effect of this practice on the gentamicin susceptibility patterns of bacterial pathogens isolated from such infections is unknown. We therefore examined the effect of a change in our prophylactic topical antibiotic exit-site protocol (from mupirocin 2% cream to gentamicin 0.1% cream) on infection rates and susceptibility patterns.
METHODS: This retrospective observational cohort study examined two periods of time: before and after the change in exit-site protocol. Each period was 30 months in duration, with a 2-month implementation period between, during which patient data were excluded. Demographic, clinical, and microbiology data were collected for each patient and episode of infection.
RESULTS: Overall, 377 patients were evaluated. In the mupirocin period (MUP), 145 infections occurred in 79 patients, and in the gentamicin period, 145 infections occurred in 93 patients. No significant effect was found either in overall episodes of infection (0.53 per year) or in episodes of peritonitis (0.429 vs 0.375 per year), but episodes of ESI increased significantly (0.098 vs 0.153 per year; p = 0.024; odds ratio: 1.55; 95% confidence interval: 1.05 to 2.28). Episodes of Staphylococcus aureus peritonitis increased by 38% (0.018 vs 0.025 per year), and episodes of S. aureus ESI increased significantly by 150% (0.022 vs 0.055 per year; p = 0.03; hazard ratio: 3.00; 95% confidence interval: 1.09 to 8.26). Episodes of pseudomonal peritonitis declined by 68% (0.022 vs 0.007 per year), and episodes of pseudomonal ESI increased by 150% (0.007 vs 0.018 per year). The gentamicin susceptibility for gram-positive isolates demonstrated no significant change; however, the gentamicin susceptibility for Enterobacteriaceae decreased by 12% and for Pseudomonas, by 14%.
CONCLUSIONS: The significant increase in episodes of ESI and the decrease in susceptibility for both Enterobacteriaceae and Pseudomonas isolates represent a concerning trend. Centers should examine trends in infection rates and in bacterial susceptibilities to determine the most appropriate agent for ESI prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302770      PMCID: PMC3524877          DOI: 10.3747/pdi.2011.00183

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  11 in total

Review 1.  Peritoneal dialysis-related infections recommendations: 2005 update.

Authors:  Beth Piraino; George R Bailie; Judith Bernardini; Elisabeth Boeschoten; Amit Gupta; Clifford Holmes; Ed J Kuijper; Philip Kam-Tao Li; Wai-Choong Lye; Salim Mujais; David L Paterson; Miguel Perez Fontan; Alfonso Ramos; Franz Schaefer; Linda Uttley
Journal:  Perit Dial Int       Date:  2005 Mar-Apr       Impact factor: 1.756

2.  Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis.

Authors:  Miguel Pérez-Fontán; Miguel Rosales; Ana Rodríguez-Carmona; Teresa García Falcón; Francisco Valdés
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

3.  Emergence of gentamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis.

Authors:  Daniel L Landry; Gregory L Braden; Stephen L Gobeille; Sarah D Haessler; Chirag K Vaidya; Stephen J Sweet
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

4.  Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection.

Authors:  R Annigeri; J Conly; S Vas; H Dedier; K P Prakashan; J M Bargman; V Jassal; D Oreopoulos
Journal:  Perit Dial Int       Date:  2001 Nov-Dec       Impact factor: 1.756

5.  Gentamicin- and silver-resistant pseudomonas in a burns unit.

Authors:  K Bridges; A Kidson; E J Lowbury; M D Wilkins
Journal:  Br Med J       Date:  1979-02-17

6.  Pseudomonas resistance to gentamicin.

Authors:  A T Ramirez; F A Melendres; C A Capili
Journal:  Scand J Plast Reconstr Surg       Date:  1979

7.  Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients.

Authors:  Judith Bernardini; Filitsa Bender; Tracey Florio; James Sloand; Linda Palmmontalbano; Linda Fried; Beth Piraino
Journal:  J Am Soc Nephrol       Date:  2004-12-29       Impact factor: 10.121

8.  A prospective study of the efficacy of local application of gentamicin versus mupirocin in the prevention of peritoneal dialysis catheter-related infections.

Authors:  Kwok Hong Chu; Wai Yee Choy; Chi Chung William Cheung; Ka Shun Fung; Hon Lok Tang; William Lee; Au Cheuk; Ka Fai Yim; Wai Han Hilda Chan; Kwok Lung Matthew Tong
Journal:  Perit Dial Int       Date:  2008 Sep-Oct       Impact factor: 1.756

9.  Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use.

Authors:  R Sutherland; R J Boon; K E Griffin; P J Masters; B Slocombe; A R White
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

10.  Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site.

Authors:  E Thodis; S Bhaskaran; P Pasadakis; J M Bargman; S I Vas; D G Oreopoulos
Journal:  Perit Dial Int       Date:  1998 May-Jun       Impact factor: 1.756

View more
  8 in total

1.  Regional variation in the treatment and prevention of peritoneal dialysis-related infections in the Peritoneal Dialysis Outcomes and Practice Patterns Study.

Authors:  Neil Boudville; David W Johnson; Junhui Zhao; Brian A Bieber; Ronald L Pisoni; Beth Piraino; Judith Bernardini; Sharon J Nessim; Yasuhiko Ito; Graham Woodrow; Fiona Brown; John Collins; Talerngsak Kanjanabuch; Cheuk-Chun Szeto; Jeffrey Perl
Journal:  Nephrol Dial Transplant       Date:  2019-12-01       Impact factor: 5.992

Review 2.  [Peritoneal dialysis from the beginnings up to today: which developments of the last decades were important?].

Authors:  Andreas Vychytil
Journal:  Wien Med Wochenschr       Date:  2013-04-17

3.  Long-Term Exit-Site Gentamicin Prophylaxis and Gentamicin Resistance in a Peritoneal Dialysis Program.

Authors:  Shan Shan Chen; Heena Sheth; Beth Piraino; Filitsa Bender
Journal:  Perit Dial Int       Date:  2015-12-03       Impact factor: 1.756

4.  Alternating Mupirocin/Gentamicin is Associated with Increased Risk of Fungal Peritonitis as Compared with Gentamicin Alone - Results of a Randomized Open-Label Controlled Trial.

Authors:  Ping-Nam Wong; Gensy M W Tong; Yuk-Yi Wong; Kin-Yee Lo; Shuk-Fan Chan; Man-Wai Lo; Kwok-Chi Lo; Lo-Yi Ho; Cindy W S Tse; Siu-Ka Mak; Andrew K M Wong
Journal:  Perit Dial Int       Date:  2016-04-04       Impact factor: 1.756

Review 5.  Peritoneal dialysis-related peritonitis: challenges and solutions.

Authors:  William L Salzer
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-06-11

6.  Peritoneal dialysis-associated infection caused by Mycobacterium abscessus: a case report.

Authors:  Ryuichi Yoshimura; Miharu Kawanishi; Shungo Fujii; Aska Yamauchi; Kentaro Takase; Kaori Yoshikane; Masahiro Egawa; Hiroaki Shiina; Takafumi Ito
Journal:  BMC Nephrol       Date:  2018-11-29       Impact factor: 2.388

7.  Simultaneous catheter removal and reinsertion, is it acceptable in M. abscessus exit site infection?

Authors:  Gajapathiraju Chamarthi; Dhruv Modi; Kenneth Andreoni; Ashutosh M Shukla
Journal:  CEN Case Rep       Date:  2021-03-16

Review 8.  ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment.

Authors:  Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Javier de Arteaga; Stanley Fan; Ana E Figueiredo; Douglas N Fish; Eric Goffin; Yong-Lim Kim; William Salzer; Dirk G Struijk; Isaac Teitelbaum; David W Johnson
Journal:  Perit Dial Int       Date:  2016-06-09       Impact factor: 1.756

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.